Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for liver cancer: pfizer tests experimental drug

NCT ID NCT07227012

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 18, 2026 · Updated 8 times

Summary

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will receive the treatment through IV infusions at clinical trial sites.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-08634404 (a biologic drug) and ipilimumab (also known as Yervoy)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced liver cancer that cannot be removed by surgery.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are possible, and the combination with ipilimumab may increase risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 138 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older at screening. * Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis. * Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies. * At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion. * Adequate hepatic, liver, and renal function * No prior systemic therapy for HCC. * ECOG performance status 0 or 1 * Child-Pugh Class A Key Exclusion Criteria: * Moderate or severe ascites. * History of hepatic encephalopathy. * Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression. * Clinically significant risk of hemorrhage or fistula. * Participants with any history of another malignancy within 3 years. * History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. * Participants with active autoimmune diseases requiring systemic treatment within the past 2 years. * Clinically significant cardiovascular disease within 6 months prior to the first dose. * Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study. * History of severe bleeding tendency or coagulation dysfunction. * History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose. * Participants with acute, chronic or symptomatic infections. * Participants with history of immunodeficiency.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver and intrahepatic bile duct neoplasm Liver Neoplasms pediatric hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced hepatocellular carcinoma Carcinoma, hepatocellular Hepatocellular cancer Hepatocellular carcinoma Liver neoplasms Metastatic hepatocellular carcinoma Unresectable hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    54 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aichi Cancer Center

    RECRUITING

    Nagoya, Aichi-ken, 464-8681, Japan

  • Allina Health Cancer Institute - Abbott Northwestern Hospital

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

  • Allina Health Cancer Institute - Mercy Hospital

    RECRUITING

    Coon Rapids, Minnesota, 55433, United States

  • Allina Health Cancer Institute - United Hospital

    RECRUITING

    Saint Paul, Minnesota, 55102, United States

  • Barnes-Jewish Hospital

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Chao Family Comprehensive Cancer Center and Ambulatory Care

    RECRUITING

    Irvine, California, 92612, United States

  • Duke Cancer Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Duke Cancer Center - Investigational Chemotherapy Service

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Duke Cancer Center Cary

    RECRUITING

    Cary, North Carolina, 27518, United States

  • Duke Cancer Center Raleigh

    RECRUITING

    Raleigh, North Carolina, 27609, United States

  • Duke University - Main Hospital and Clinics

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • Keck Hospital of USC

    RECRUITING

    Los Angeles, California, 90033, United States

  • Keck Medical Center of USC Pasadena

    RECRUITING

    Pasadena, California, 91105, United States

  • Kindai University Hospital- Osaka Medical Campus

    RECRUITING

    Sakai, Osaka, 590-0197, Japan

  • Los Angeles General Medical Center

    RECRUITING

    Los Angeles, California, 90033, United States

  • Memorial Hospital

    RECRUITING

    Shiloh, Illinois, 62269, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • Moffitt Cancer Center - International Plaza

    RECRUITING

    Tampa, Florida, 33607, United States

  • Moffitt Cancer Center - McKinley Campus

    RECRUITING

    Tampa, Florida, 33612, United States

  • Moffitt Cancer Center at SouthShore

    RECRUITING

    Ruskin, Florida, 33570, United States

  • Moffitt Cancer Center at Speros

    RECRUITING

    Land O' Lakes, Florida, 34638, United States

  • Moffitt Cancer Center at Wesley Chapel

    RECRUITING

    Wesley Chapel, Florida, 33544, United States

  • Moffitt McKinley Hospital

    RECRUITING

    Tampa, Florida, 33612, United States

  • National Cancer Center Hospital

    RECRUITING

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa, Chiba, 277-8577, Japan

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, 704, Taiwan

  • National Hospital Organization Kyushu Cancer Center

    RECRUITING

    Fukuoka, 811-1395, Japan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 10002, Taiwan

  • Pan American Center for Oncology Trials, LLC

    RECRUITING

    San Juan, 00909, Puerto Rico

  • Pan American Center for Oncology Trials, LLC - Dorado Office

    RECRUITING

    Dorado, United States of America, 00646, Puerto Rico

  • Pan American Center for Oncology Trials, LLC - Mayaguez Office

    RECRUITING

    Mayagüez, United States of America, 00680, Puerto Rico

  • Pan American Center for Oncology Trials, LLC - Ponce Office

    RECRUITING

    Ponce, United States of America, 00730, Puerto Rico

  • Renown Health Medical Oncology

    RECRUITING

    Reno, Nevada, 89502, United States

  • Renown Office of Clinical Research

    RECRUITING

    Reno, Nevada, 89502, United States

  • Renown Regional Medical Center

    RECRUITING

    Reno, Nevada, 89502, United States

  • Saint Luke's Cancer Institute

    RECRUITING

    Kansas City, Missouri, 64111, United States

  • Saint Luke's Hospital of Kansas City

    RECRUITING

    Kansas City, Missouri, 64111, United States

  • Siteman Cancer Center

    RECRUITING

    St Louis, Missouri, 63108, United States

  • Siteman Cancer Center - North County

    RECRUITING

    Florissant, Missouri, 63031, United States

  • Siteman Cancer Center - Shiloh

    RECRUITING

    Shiloh, Illinois, 62269, United States

  • Siteman Cancer Center - South County

    RECRUITING

    St Louis, Missouri, 63129, United States

  • Siteman Cancer Center - St. Peters

    RECRUITING

    City of Saint Peters, Missouri, 63376, United States

  • Siteman Cancer Center - West County

    RECRUITING

    Creve Coeur, Missouri, 63141, United States

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, 407, Taiwan

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 112, Taiwan

  • UC Irvine Health - Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

  • UCI Health - Irvine

    RECRUITING

    Irvine, California, 92612, United States

  • UCI Health - Irvine Infusion Pharmacy ACC

    RECRUITING

    Irvine, California, 92612, United States

  • USC/Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services

    RECRUITING

    Los Angeles, California, 90033, United States

  • University of Washington Medical Center- Montlake

    RECRUITING

    Seattle, Washington, 98195, United States

  • Virginia Mason Medical Center

    NOT_YET_RECRUITING

    Seattle, Washington, 98101, United States

  • Washington University School of Medicine - Siteman Cancer Center

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.